QUOTED. 30 March 2021. Eli Casdin.
Blank-check company CM Life Sciences II signed an agreement to merge with proteomics company SomaLogic, a deal valued at $1.25bn. See what Eli Casdin, CEO of CM Life Sciences II said about it here.
“The long-promised power of proteomics is quickly becoming a commercial and clinical reality, and in our view, SomaLogic is the leading platform in the field. What is needed is to accelerate this transformation from promise to reality is human and financial capital, and the CMS II team could not be more honored to provide both through this merger.” – Eli Casdin, CEO, CM Life Sciences II
Click here for a free trial of Medtech Insight